Kadimastem Ltd (KMSTF)
Stock analysis · OTC · Healthcare · Biotechnology
Kadimastem Ltd (KMSTF) is a publicly traded company in the Healthcare sector. Latest price: $3.21. Market cap $9.50M. Trailing PE -1.58. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →1-Year Price
Proprietary Signals
About Kadimastem Ltd
Kadimastem Ltd, an Israeli biopharmaceutical company, focuses on pioneering regenerative medicine therapies that utilize cells originating from human embryonic stem cells, primarily targeting neurodegenerative disorders. Its developmental pipeline features AstroRx, a clinical-grade human astrocyte therapy presently undergoing Phase 1/2a clinical trials for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. Additionally, the company is developing IsletRx, a clinical-grade pancreatic islet cell therapy designed to treat diabetes. Founded in 2008, Kadimastem maintains its headquarters in Ness Ziona, Israel.
Valuation
| P/E (TTM) | -1.58× |
|---|---|
| P/S (TTM) | 0.00× |
| P/B | -1.44× |
| P/FCF (TTM) | -10.68× |
| EV / EBITDA | -2.23× |
| EV / Sales | 0.00× |
| Earnings Yield | -63.07% |
| Free Cash Flow Yield | -9.36% |
Fundamentals
| Enterprise Value | $55.46M |
|---|---|
| Net Income (TTM) | -$18.71M |
| Free Cash Flow (TTM) | -$2.60M |
| Net Debt | $25.80M |
| Working Capital | -$29.60M |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | 158.13% |
| Return on Invested Capital | 678.62% |
Peers
Recent News
- No recent news available.
Related
Browse more tickers: sitemap